These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16422914

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
    Shamloul R, El-Dakhly M, Ghanem H, Gadallah A, Mokhtar H.
    J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients.
    Fu Q, Yao DH, Jiang YQ.
    Asian J Androl; 2000 Dec; 2(4):301-3. PubMed ID: 11202421
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction.
    Lammers PI, Rubio-Aurioles E, Castell R, Castaneda J, Ponce de Leon R, Hurley D, Lipezker M, Loehr LA, Lowrey F.
    Int J Impot Res; 2002 Feb; 14(1):54-9; discussion 60. PubMed ID: 11896479
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
    Seyam R, Mohamed K, Akhras AA, Rashwan H.
    Int J Impot Res; 2005 Feb; 17(4):346-53. PubMed ID: 15772683
    [Abstract] [Full Text] [Related]

  • 9. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S, Niv E, Livne PM, Shmueli J, Engelstein D, Segenreich E, Baniel J.
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [Abstract] [Full Text] [Related]

  • 10. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R, Melman A.
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [Abstract] [Full Text] [Related]

  • 11. How safe is the treatment of impotence with intracavernous autoinjection?
    Zentgraf M, Ludwig G, Ziegler M.
    Eur Urol; 1989 Jun; 16(3):165-71. PubMed ID: 2663519
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S, Schoor R, Elmogy M, Ross L, Hegazy A, Niederberger C.
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [Abstract] [Full Text] [Related]

  • 14. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine.
    Brown SL, Haas CA, Koehler M, Bodner DR, Seftel AD.
    Urology; 1998 Nov; 52(5):844-7. PubMed ID: 9801111
    [Abstract] [Full Text] [Related]

  • 15. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence.
    Gasser TC, Roach RM, Larsen EH, Madsen PO, Bruskewitz RC.
    J Urol; 1987 Apr; 137(4):678-80. PubMed ID: 3550149
    [Abstract] [Full Text] [Related]

  • 16. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
    Wyndaele JJ, de Meyer JM, de Sy WA, Claessens H.
    Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
    [Abstract] [Full Text] [Related]

  • 17. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
    de Boer BJ, Lycklama a Nijeholt AA, Kleinjans HA.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):783-7. PubMed ID: 11346917
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN, Hamed HA, Kamel II, Shamloul RM, Ghanem HM.
    Int J Impot Res; 2004 Apr 21; 16(2):143-5. PubMed ID: 15014552
    [Abstract] [Full Text] [Related]

  • 20. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy.
    McMahon CG.
    Int J Impot Res; 2003 Oct 21; 15(5):383-4. PubMed ID: 14562142
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.